NIH-Funded Study Shows Puberty Blockers Don't Improve Youth Mental Health, So Funding Should Stop
Source: Douglas Napier. "Delayed Study Finds Puberty Blockers Don't Help Kids." September 1, 2026. thefederalist.com
The Gist
The author argues that a long-delayed government-funded study shows puberty blockers don't actually help kids' mental health, while carrying serious physical risks. Because of this and because other countries and even some companies have already stopped covering these treatments, he says all corporations and government programs should stop paying for them too.
Conclusion
Companies and public programs should stop funding puberty blockers and other 'gender-affirming' medical interventions for minors.
Premises
- A major NIH-funded study (led by a pro-trans researcher) tracking ~95 youth on puberty blockers over 24 months found no significant improvement in depression symptoms, emotional functioning, or behavioral measures.
- The study's lead researcher allegedly delayed publishing the results for years because they did not want the findings 'weaponized,' suggesting the data contradicts the pro-treatment narrative.
- These interventions carry serious, often irreversible physical risks (loss of fertility, diminished bone density, chronic infections, sexual dysfunction, interference with normal development).
- Multiple European countries (UK, Sweden, Finland, Norway) have independently reviewed the evidence and restricted or abandoned these treatments for minors.
- The 2025 HHS evidence review and 'Wolves in White Coats' report found weak evidence, significant risks, and profit-driven incentives behind the expansion of these treatments.
- WPATH, whose Standards of Care justified insurance coverage, has now admitted in court that its guidance is merely 'opinion' amid 'medical and scientific uncertainty,' undermining claims that these treatments are 'medically necessary.'
- Some companies (Charles Schwab, Walmart) and the federal government (via CMS Medicaid/CHIP rule) have already ended funding for these procedures for minors, demonstrating a viable and responsible alternative path.
Assumptions
- A single study's failure to show statistically significant improvement in the measured metrics proves the treatments are ineffective for all patients, not merely inconclusive or limited in scope.
- Improved mental health metrics within 24 months would be the appropriate primary measure of the treatments' value, rather than dysphoria reduction, quality of life, or long-term outcomes.
- The motives attributed to the lead researcher (delaying publication to protect a narrative) accurately reflect why publication was delayed, rather than other explanations (e.g., methodological revisions, small sample size complications).
- Corporate and government funding decisions should be based primarily on this single study and related reports rather than a broader body of research or ongoing scientific debate.
- The comparison to historical discredited treatments like lobotomies is a fair analogy to current puberty blocker therapy.
- WPATH's court statements about 'uncertainty' in litigation context are equivalent to an admission that no treatment protocol has clinical validity.